Partner Headlines - ARNA

  1. Benzinga's Top #PreMarket Losers

    Benzinga
  2. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  3. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  6. FDA delays Orexigen drug

    IBD
  7. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  8. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  9. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  10. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  11. Earnings Scheduled For May 12, 2014

    Benzinga
  12. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Earnings Scheduled For February 27, 2014

    Benzinga
  15. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  16. Top Trending Tickers On StockTwits For February 14

    Benzinga
  17. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  18. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  19. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  20. The Top Five Drug Launches Of 2013

    IBD
  21. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  24. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  25. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  26. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  27. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  28. Benzinga's Top #PreMarket Losers

    Benzinga
  29. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  30. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  31. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  32. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  33. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  34. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  35. Benzinga's Top Pre-Market Losers

    Benzinga
  36. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  37. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  38. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  39. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  40. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  41. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  42. Stocks Hitting 52-Week Lows

    Benzinga
  43. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  44. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  45. Stocks Hitting 52-Week Lows

    Benzinga
  46. Stocks Hitting 52-Week Lows

    Benzinga
  47. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  48. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  49. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  50. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  51. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  52. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  53. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  54. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  55. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  56. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  57. Vivus fell 4.2% to 13.72

    IBD
  58. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  59. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  60. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  61. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  62. Benzinga's Top Pre-Market Gainers

    Benzinga
  63. The Best Small Cap Performers of 2012

    Benzinga
  64. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  65. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  66. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  67. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  68. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  69. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  70. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  71. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  72. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  73. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  74. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  75. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  76. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  77. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  78. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  79. Short Sellers Shy Away from Biotech Firms

    Benzinga
  80. Benzinga's Top Pre-Market Gainers

    Benzinga
  81. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  82. Health Care Sector Wrap

    FoxBusiness
  83. Short Interest in Biotech Firms on the Rise

    Benzinga
  84. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  85. Health Care Sector Wrap

    FoxBusiness
  86. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  87. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  88. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  89. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
  90. Arena Pharmaceuticals (ARNA) Falls 8.3% After Rival Weight Loss ...

    MarketIntelligenceCenter
  91. Wednesday Market Movers

    Benzinga
  92. Vivus Stock Jumps 12.5% On Drug Approval

    IBD
  93. Benzinga's Top Pre-Market Losers

    Benzinga
  94. Drug Stocks Up On Glaxo, Par M&A And Gilead HIV Pill

    IBD
  95. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  96. Stocks Move Lower as Euro Zone and Earnings Worries Persist with ...

    MarketIntelligenceCenter
  97. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  98. Benzinga's Top Pre-Market Gainers

    Benzinga
  99. Arena Pharmaceuticals Inc. (ARNA) SVP, Finance and CFO Robert ...

    GuruFocus
  100. Health Care Sector Wrap

    FoxBusiness
Trading Center